Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors formetastatic melanoma

JAMA Dermatology

Volumn 151, Issue 10, 2015, Pages 1103-1109

  Carlos, Giuliana ^a,b   Anforth, Rachael ^a,b   Clements, Arthur ^b,c,d,e   Menzies, Alexander M ^b,c,d,e   Carlino, Matteo S ^b,c,d,e   Chou, Shaun ^a   Fernandez Peñas, Pablo ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b University of Sydney   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d BLACKTOWN HOSPITAL   (Australia)

^e MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; DABRAFENIB; METHOTREXATE; PENICILLIN DERIVATIVE; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE;

ACNE; ACTINIC KERATOSIS; ADULT; ADVERSE DRUG REACTION; AGE DISTRIBUTION; ANGIOMA; ARTICLE; AUSTRALIAN; BASAL CELL CARCINOMA; CANCER STAGING; CHEST ERYTHEMA; COHORT ANALYSIS; CONTROLLED STUDY; DARIER DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA; FACE ERYTHEMA; FEMALE; FOLLICULITIS; GRANULOMA ANNULARE; HAIR COLOR; HAIR LOSS; HEMANGIOMA; HUMAN; HYPERKERATOSIS; INFLAMMATION; INOPERABLE CANCER; KERATOSIS; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; PANNICULITIS; PATIENT MONITORING; PHOTOSENSITIVITY; PLANTAR HYPERKERATOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN CARCINOMA; TRANSIENT ACANTHOLYTIC DERMATOSIS; TREATMENT DURATION; VERRUCA VULGARIS; VERRUCAL KERATOSIS; VITILIGO; AGED; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPARATIVE STUDY; METASTASIS; MIDDLE AGED; PATHOLOGY; PREVALENCE; SKIN DISEASES; SKIN NEOPLASMS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OXIMES; PREVALENCE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; RETROSPECTIVE STUDIES; SKIN DISEASES; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84944350959     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.1745     Document Type: Article

References (30)

1. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
2. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-365.
3. Flaherty KT, Robert C, Hersey P, et al; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-114.
4. ™) combination demonstrated overall survival benefit compared to vemurafenib: phase III BRAF V600-mutant metastatic melanoma study stopped early. http://us.gsk.com/en-us/media/press-releases/2014/trametinib-mekinist-and-dabrafenib-tafinlar-combination-demonstrated-overall-survival-benefit-compared-to-vemurafenib-phase-iii-braf-v600-mutant-metastatic-melanoma-study-stopped-early/. Accessed July 2014.
5. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-1703.
6. Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14(1):e11-e18. doi:10.1016/S1470-2045 (12) 70413-8.
7. Anforth R, Liu M, Nguyen B, et al. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol. 2014;55(4):250-254.
8. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ. 1995;310(6973):170.
9. Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patientswith metastatic melanoma. Br J Dermatol. 2012;167(5):1153-1160.
10. Cancer Council Australia. Clinical practice guide: basal cell carcinoma, squamous cell carcinoma (and related lesions) - a guide to clinical management in Australia. 2008. http://www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/Basal-cell-carcinoma-Squamous-cell-carcinoma-Guide-Nov-2008-Final-with-Corrigendums.pdf. Accessed July 2013.
11. Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol. 2012;148(5):628-633.
12. Ma L, Dominguez AR, Collins GR, Kia KF, Cockerell CJ. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib. Arch Dermatol. 2012;148(12):1428-1429.
13. Belum VR, Fischer A, Choi JN, Lacouture ME. Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep. 2013;15(3):249-259.
14. Curry JL, Torres-Cabala CA, Kim KB, et al. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol. 2014;53(3):376-384.
15. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209-221.
16. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431-435.
17. King AJ, Arnone MR, Bleam MR, et al. Dabrafenib: preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One. 2013;8(7):e67583. doi:10.1371/journal.pone.0067583.
18. Anforth R, Fernandez-Penas P. BRAF inhibitor induced verrucal keratosis [comment]. Am J Dermatopathol. 2014;36(2):192.
19. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
20. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-Mutant Melanoma Metastatic to the Brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087-1095.
21. Sharma A, Shah SR, Illum H, Dowell J. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. Drugs. 2012;72(17):2207-2222.
22. Chu EY, Wanat KA, Miller CJ, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012;67(6):1265-1272.
23. Gelot P, Dutartre H, Khammari A, et al. Vemurafenib: an unusual UVA-induced photosensitivity. Exp Dermatol. 2013;22(4):297-298.
24. Vanneste L, Wolter P, Van den Oord JJ, Stas M, Garmyn M. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. J Eur Acad Dermatol Venereol. 2015;29(1):61-68.
25. Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691-1697.
26. Uribe P, Anforth RM, Kefford RF, Fernandez-Peñas P. Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy. Melanoma Res. 2014;24(5):501-503.
27. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714.
28. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30(19):2375-2383.
29. Yagerman S, Flores E, Busam K, Lacouture M, Marghoob AA. Overviewphotography and short-term mole monitoring in patients taking a BRAF inhibitor. JAMA Dermatol. 2014;150(9):1010-1011.
30. Zimmer L, Haydu LE, Menzies AM, et al. Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. J Clin Oncol. 2014;32(8):816-823.